首页> 外文期刊>International Urology and Nephrology >High-density lipoprotein in uremic patients: metabolism, impairment, and therapy
【24h】

High-density lipoprotein in uremic patients: metabolism, impairment, and therapy

机译:尿毒症患者的高密度脂蛋白:代谢,损伤和治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Several studies have shown that HDL has altered antioxidant and anti-inflammatory effects in chronic uremia, either by the reduction in its antioxidant enzymes or by the impairment of their activity. Systemic oxidative stress, which is highly prevalent in chronic kidney disease (CKD) patients, has been shown to decrease antioxidant and anti-inflammatory effects of HDL and even transform it into a pro-oxidant and pro-inflammatory agent. For this reason, we believe that the propensity for accelerated cardiovascular disease in CKD is facilitated by a few key features of this disease, namely, oxidative stress, inflammation, hypertension, and disorders of lipid metabolism. In a nutshell, oxidative stress and inflammation enhance atherosclerosis leading to increased cardiovascular mortality and morbidity in this population. In this detailed review, we highlight the current knowledge on HDL dysfunction and impairment in chronic kidney disease as well as the available therapy.
机译:几项研究表明,HDL通过减少其抗氧化酶或其活性而改变了慢性尿毒症的抗氧化和抗炎作用。在慢性肾脏病(CKD)患者中普遍存在的全身性氧化应激可降低HDL的抗氧化和抗炎作用,甚至可将其转变为促氧化剂和促炎剂。因此,我们认为该疾病的一些关键特征(即氧化应激,炎症,高血压和脂质代谢紊乱)促进了CKD加速心血管疾病的发生。简而言之,氧化应激和炎症会加剧动脉粥样硬化,从而导致该人群的心血管疾病死亡率和发病率增加。在这篇详细的综述中,我们重点介绍了慢性肾脏疾病中HDL功能障碍和损害的最新知识以及可用的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号